{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "34859487",
  "DateCompleted": {
    "Year": "2022",
    "Month": "04",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "05",
    "Day": "31"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "12",
        "Day": "27"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1111/ced.15039"
    ],
    "Journal": {
      "ISSN": "1365-2230",
      "JournalIssue": {
        "Volume": "47",
        "Issue": "4",
        "PubDate": {
          "Year": "2022",
          "Month": "Apr"
        }
      },
      "Title": "Clinical and experimental dermatology",
      "ISOAbbreviation": "Clin Exp Dermatol"
    },
    "ArticleTitle": "First use of the Adolescent Depression Rating Scale (ADRS) in the management of young people with severe acne treated with isotretinoin: a pilot study of an active monitoring of depressive disorders by dermatologists.",
    "Pagination": {
      "StartPage": "709",
      "EndPage": "716",
      "MedlinePgn": "709-716"
    },
    "Abstract": {
      "AbstractText": [
        "During isotretinoin treatment, special attention is required to detect any symptom or change in the mental health of patients. The monitoring is complex for adolescents because of confounding factors such as mood changes associated with adolescence and puberty and the higher psychosocial impairment due to the acne itself.",
        "To determine the utility of the Adolescent Depression Rating Scale (ADRS) for monitoring symptoms in adolescents before and during isotretinoin treatment in dermatology real-life practice.",
        "This was a national, multicentre prospective study that enrolled a random sample of dermatologists treating adolescents. An algorithm including ADRS score and its changes between consecutive visits was used. At each visit, dermatologists rated their satisfaction with ADRS and its ease of use, while patients rated the acceptability of the ADRS.",
        "In total, 70 dermatologists used the algorithm for 1227 visits of 283 adolescents receiving isotretinoin. Of these 70 dermatologists, 80.8% were satisfied/very satisfied with the ADRS, 82.7% considered the use of the ADRS in clinical practice to be easy/very easy and 75% considered that the ADRS enabled them to discuss more easily the risk of depression with their patients. For the patients, acceptability of the ADRS was considered good by 93.8%.",
        "The implementation of the ADRS could be valuable in dermatology practice, optimizing the monitoring of patients and the good use of isotretinoin."
      ],
      "CopyrightInformation": "\u00a9 2021 British Association of Dermatologists."
    },
    "AuthorList": [
      {
        "Identifier": [
          "0000-0003-1401-3788"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Dermatology, Grand H\u00f4pital Est Francilien, Jossigny, France."
          }
        ],
        "LastName": "Hefez",
        "ForeName": "L",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de Pharmacologie Clinique et Pharmacovigilance, Pharmacometry and Pharmacoepidemiology, Institut de Neurosciences des Syst\u00e8mes, APHM/INSERM/Aix Marseille University, Marseille, France."
          }
        ],
        "LastName": "Micallef",
        "ForeName": "J",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Adolescent Psychiatry, Centre Hospitalier Victor Dupouy, Argenteuil, France."
          },
          {
            "Identifier": [],
            "Affiliation": "ECSTRRA team, Statistic And Epidemiological Research Centre Sorbonne Paris Cit\u00e9 (CRESS), INSERM U1153, Universit\u00e9 de Paris, Paris, France."
          }
        ],
        "LastName": "Revah-Levy",
        "ForeName": "A",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "INSERM U669, Paris-Sud 11 University, APHP, Villejuif, France, Paris, France."
          }
        ],
        "LastName": "Falissard",
        "ForeName": "B",
        "Initials": "B"
      },
      {
        "Identifier": [
          "0000-0002-4873-6522"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Service de Pharmacologie Clinique et Pharmacovigilance, Pharmacometry and Pharmacoepidemiology, Institut de Neurosciences des Syst\u00e8mes, APHM/INSERM/Aix Marseille University, Marseille, France."
          }
        ],
        "LastName": "Jouve",
        "ForeName": "E",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Onco-Dermatology Department, CHU Nantes, CRCINA, Nantes University, Nantes, France."
          }
        ],
        "LastName": "Dreno",
        "ForeName": "B",
        "Initials": "B"
      },
      {
        "Identifier": [
          "0000-0002-8400-4310"
        ],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Dermatology, APHP, H\u00f4pital Henri-Mondor, Facult\u00e9 de Sant\u00e9, Paris-Est, Cr\u00e9teil, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Research Group Dynamic, EA7380, Facult\u00e9 de Sant\u00e9 de Cr\u00e9teil, \u00c9cole Nationale V\u00e9t\u00e9rinaire d'Alfort, USC ANSES, Universit\u00e9 Paris-Est Cr\u00e9teil, Cr\u00e9teil, France."
          },
          {
            "Identifier": [],
            "Affiliation": "Centre de Preuves de la Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie, Paris, France."
          }
        ],
        "LastName": "Chosidow",
        "ForeName": "O",
        "Initials": "O"
      }
    ],
    "GrantList": [
      {
        "Agency": "Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9",
        "Country": ""
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Multicenter Study"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Clin Exp Dermatol",
    "NlmUniqueID": "7606847",
    "ISSNLinking": "0307-6938"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Dermatologic Agents"
    },
    {
      "RegistryNumber": "EH28UP18IF",
      "NameOfSubstance": "Isotretinoin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "drug therapy",
        "psychology"
      ],
      "DescriptorName": "Acne Vulgaris"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "etiology"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "etiology"
      ],
      "DescriptorName": "Depressive Disorder"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Dermatologic Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Dermatologists"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Isotretinoin"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pilot Projects"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prospective Studies"
    }
  ]
}